Kura Oncology (NASDAQ:KURA) Issues Quarterly Earnings Results

Kura Oncology (NASDAQ:KURA) released its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.04, Briefing.com reports. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.53) EPS.

Kura Oncology Trading Down 0.8 %

Shares of KURA stock traded down $0.15 on Friday, reaching $18.97. 1,107,395 shares of the company’s stock were exchanged, compared to its average volume of 1,047,496. Kura Oncology has a 52 week low of $7.41 and a 52 week high of $24.17. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.45 billion, a PE ratio of -8.74 and a beta of 0.88. The company’s fifty day simple moving average is $20.74 and its 200 day simple moving average is $20.69.

Insider Buying and Selling

In related news, insider Teresa Brophy Bair sold 2,615 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $22.15, for a total transaction of $57,922.25. Following the completion of the sale, the insider now directly owns 68,979 shares of the company’s stock, valued at approximately $1,527,884.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on KURA. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Tuesday, June 18th. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, April 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Friday. Stifel Nicolaus dropped their target price on Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Monday, June 24th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $30.57.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.